Last reviewed · How we verify
Evusheld (TIXAGEVIMAB)
Evusheld (generic name: TIXAGEVIMAB) is a Monoclonal antibody drug developed by AstraZeneca. It is currently FDA-approved for COVID-19.
At a glance
| Generic name | TIXAGEVIMAB |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Monoclonal antibody |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- COVID-19
Common side effects
Key clinical trials
- REAl LIfe" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (PHASE1)
- Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (PHASE2,PHASE3)
- AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (PHASE3)
- eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services
- Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PHASE3)
- Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Evusheld CI brief — competitive landscape report
- Evusheld updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Evusheld
What is Evusheld?
Evusheld (TIXAGEVIMAB) is a Monoclonal antibody drug developed by AstraZeneca, indicated for COVID-19.
What is Evusheld used for?
Evusheld is indicated for COVID-19.
Who makes Evusheld?
Evusheld is developed and marketed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).
What is the generic name of Evusheld?
TIXAGEVIMAB is the generic (nonproprietary) name of Evusheld.
What development phase is Evusheld in?
Evusheld is FDA-approved (marketed).
Related
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for COVID-19
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing